Sanofi Gains Approval for Bleeding-Disorder Treatments in China
Sanofi has achieved a major milestone by securing approval for two innovative bleeding‑disorder treatments in China, as announced recently by the company and local regulators. The Chinese National Medical Products Administration (NMPA) granted approvals for Qfitlia and Cablivi, two specialized medicines designed to treat rare and serious blood disorders, strengthening Sanofi’s presence in one of the world’s largest pharmaceutical markets.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
